Pheochromocytoma/Paraganglioma Clinical Trials

7 recruitingLast updated: June 17, 2026

There are 7 actively recruiting pheochromocytoma/paraganglioma clinical trials across 23 countries. Studies span Phase 2, Not Applicable, Phase 1. Top locations include Bethesda, Maryland, United States, Beijing, Beijing Municipality, China, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


Pheochromocytoma/Paraganglioma Trials at a Glance

7 actively recruiting trials for pheochromocytoma/paraganglioma are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Bethesda, Beijing, and Shanghai. Lead sponsors running pheochromocytoma/paraganglioma studies include National Cancer Institute (NCI), Fudan University, and José Claudio Casali da Rocha.

Browse pheochromocytoma/paraganglioma trials by phase

Treatments under study

About Pheochromocytoma/Paraganglioma Clinical Trials

Looking for clinical trials for Pheochromocytoma/Paraganglioma? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pheochromocytoma/Paraganglioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pheochromocytoma/Paraganglioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Nasopharyngeal CarcinomaKidney CancersEsthesioneuroblastoma+7 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC355 enrolled84 locationsNCT04924075
Recruiting
Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Pancreatic CancerHereditary Breast and Ovarian CancerHodgkin Lymphoma+43 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting
Not Applicable

Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma

Pheochromocytoma/Paraganglioma (PPGL)
Peking Union Medical College Hospital40 enrolled1 locationNCT07288931
Recruiting
Phase 2

Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

Von Hippel-Lindau DiseasePheochromocytoma/ParagangliomaVon Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma+5 more
José Claudio Casali da Rocha100 enrolled1 locationNCT07167329
Recruiting
Phase 2

Ivonescimab in the Treatment of Multiple Advanced Tumors

Urothelial CarcinomaSarcomaKidney Cancer+16 more
Fudan University400 enrolled1 locationNCT06683846